시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 종양학용 AI 시장 예측(-2030년) : 기업 유형(통합 스위트), 용도(Drug Discovery, 신약 설계, 진단, 정밀의료, 게놈), 기술(CNN, NLP), 암 유형(폐암), 최종사용자(병원, 제약 기업), 지역별
AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Diagnosis, Precision Medicine, Genomic), Technology (CNN, NLP), Cancer Type (Lung), End User (Hospitals, Pharma),& Region-Global Forecast to 2030
상품코드 : 1632129
리서치사 : MarketsandMarkets
발행일 : 2024년 12월
페이지 정보 : 영문 581 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,950 ￦ 7,146,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,650 ￦ 9,601,000
PDF (5-user License) help
PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,150 ￦ 11,766,000
PDF (Corporate License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,438,000
PDF (Global License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

종양학용 AI 시장 규모는 2024년 24억 5,000만 달러에서 예측 기간 중 29.4%의 CAGR로 추이하며, 2030년에는 115억 2,000만 달러 규모로 성장할 것으로 예측됩니다.

이 시장의 성장을 이끄는 요인으로는 비용 효율적인 암 치료 및 솔루션에 대한 수요 증가, 신약 개발 프로세스의 간소화, 의료 기록 및 환자 데이터의 급속한 디지털화, 암 사례 증가, 규제 준수 요건 등이 있습니다.

조사 범위
조사 대상연도 2022-2030년
기준연도 2023년
예측 기간 2024-2030년
검토 단위 금액(달러)
부문별 기업 유형·용도·암 유형·기술·도입 모델·최종사용자별
대상 지역 북미·유럽·아시아태평양·라틴아메리카·중동 & 아프리카

세계의 종양학용 AI 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 분석, 기술·특허의 동향, 법규제 환경, 사례 연구, 시장 규모 추이·예측, 각종 구분·지역별 상세 분석, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 주요 인사이트

제5장 시장 개요

제6장 종양학용 AI 시장 : 기술별

제7장 종양학용 AI 시장 : 용도별

제8장 종양학용 AI 시장 : 암 유형별

제9장 종양학용 AI 시장 : 최종사용자별

제10장 종양학용 AI 시장 : 기업 유형별

제11장 종양학용 AI 시장 : 도입 모델별

제12장 종양학용 AI 시장 : 지역별

제13장 경쟁 구도

제14장 기업 개요

제15장 부록

KSA
영문 목차

영문목차

The global AI in Oncology market is projected to reach USD 11.52 billion by 2030 from USD 2.45 billion in 2024, at a CAGR of 29.4% from 2024 to 2030. The market's growth is fuelled by the growing demand for cost-effective cancer treatments & solutions, streamlining of the drug discovery process, rapid digitization of healthcare records and patient data, the growing volume of cancer cases, and regulatory compliance requirements.

Scope of the Report
Years Considered for the Study2022-2030
Base Year2023
Forecast Period2024-2030
Units ConsideredValue (USD)
SegmentsBy Player Type, Application, Cancer Type, Technology, Deployment Model, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East Africa.

In March 2024, the journal published by the American Cancer Society stated the following key points:

However, integration with existing healthcare systems, data privacy, and security constraints pose a significant challenge within this market.

"Machine learning held the largest share in technology type in the AI in oncology market in 2023."

The AI in oncology market is segmented based on technology into machine learning, natural language processing (NLP), context-aware processing and computing, computer vision, and image analysis (including optical character recognition). The machine learning segment held the largest market share in 2023. Further, the machine learning segment includes deep learning (including convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies. Among these, deep learning is the largest segment owing to its capability to analyze and process vast and complex datasets including medical images with improved efficiency. Within deep learning technologies such as CNNs are effective for image-based cancer detection, while RNNs and GANs are used to improve the temporal pattern analysis and data synthesis. Moreover, deep learning's scalability, adaptability and precision in analyzing and identifying the subtle patterns in cancer helped in improving the diagnosis, risk predictions and treatment optimization.

"By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period."

By player type, the AI in oncology market is divided into niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers. The integrated suite/platform providers segment accounts for the largest and is projected to be the fastest-growing segment over the forecast year. "By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period." The growth is attributed to the fact that these providers offer comprehensive end-to-end solutions to streamline workflows across all treatment sectors of cancer such as detection, diagnosis, monitoring, and treatment planning. Such platforms help to integrate technologies including NLP, computer vision, and machine learning resulting in better clinical decision-making and offering seamless data interoperability.

Moreover, integrated suite/platform helps in decreasing the need for multiple vendors as they are unified systems due to their scalability and flexibility which results in cost effective solution. This holistic approach drives adoption and fuels rapid growth.

"Asia Pacific is estimated to register the highest CAGR over the forecast period."

The AI in Oncology market is segmented mainly into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The AI in oncology market in Asia Pacific is projected to register at the highest CAGR rate during the forecast period. The growth of this region is due to the development of healthcare infrastructure, and government initiatives to modernize and digitalize the healthcare industry particularly due to rising cancer cases, growth in minimally invasive cancer treatments, and to increase in the survival rate of cancer patients. Countries such as Japan, China, and India are focusing on developing cost-effective solutions in cancer care emphasizing the importance of AI-driven data management to handle sensitive patient information and ensure compliance with regulatory mandates for healthcare data standardization. Various key players and startups in the countries are promoting AI use in cancer such as Niramai, a Bangalore-based health tech startup, developed Thermalytix, an AI-driven breast cancer screening solution. The technology uses non-invasive, radiation-free thermal imaging and machine learning algorithms to detect breast cancer at an earlier stage compared to traditional methods. The solution is designed for all ages and ensures privacy, portability, and high accuracy. It is available in over 30 cities across 200+ hospitals in India and is expanding globally to different countries, thereby, transforming preventive cancer care.

Breakdown of supply-side primary interviews by company type, designation, and region:

List of Companies Profiled in the Report

Research Coverage

This research report categorizes the AI in oncology market by player type [niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers], by application [drug discovery {target identification & validation, lead identification & optimization, de novo drug design}, drug development {preclinical testing, predictive modeling for human trials, clinical trial optimization, adaptive trial design & monitoring}, diagnosis & early detection {imaging & radiology (mammography, computed tomography, magnetic resonance imaging (MRI), nuclear imaging (PET & SPECT), X-ray imaging, ultrasound, others), digital pathology & histopathology, liquid biopsy & biomarker detection, genetic risk prediction}, treatment planning & personalization {personalized treatment planning (precision medicine & genomic analysis, radiomics and radiogenomics, predictive models for treatment response, treatment recommendation systems), radiation therapy, chemotherapy, immunotherapy, targeted therapy (combination & dose optimization, AI-guided drug delivery), surgical planning & assistance (preoperative imaging and 3D modeling, intraoperative guidance and robotics, postoperative analysis & recovery)}, patient engagement & remote monitoring {symptom management & virtual assistance, remote patient monitoring, patient education & empowerment}, post-treatment surveillance & survivorship care {recurrence monitoring, long-term outcome prediction, mental health & support systems}, data management & analytics, other applications, by cancer type (solid tumors [including breast cancer lung cancer, prostate cancer, colorectal cancer, brain tumors, and other tumors], hematologic malignancies (including leukemia, lymphoma, multiple myeloma, other hematologic malignancies), by technology [machine learning {deep learning (convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies}, natural language processing (NLP), context-aware processing and computing, computer vision, image analysis (including optical character recognition)], by deployment [on-premises model, cloud-based model, and hybrid model], by end user [healthcare providers {hospitals & clinics, specialty centers, laboratories & diagnostic centers, others}, pharmaceutical & biotechnology companies, medical device/equipment companies, academic & research institutions, government & regulatory agencies, healthcare payers, and others}, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in oncology market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in oncology market. Competitive analysis of upcoming startups in the AI in oncology market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in oncology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 AI IN ONCOLOGY MARKET, BY TECHNOLOGY

7 AI IN ONCOLOGY MARKET, BY APPLICATION

8 AI IN ONCOLOGY MARKET, BY CANCER TYPE

9 AI IN ONCOLOGY MARKET, BY END USER

10 AI IN ONCOLOGY MARKET, BY PLAYER TYPE

11 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL

12 AI IN ONCOLOGY MARKET, BY REGION

13 COMPETITIVE LANDSCAPE

14 COMPANY PROFILES

15 APPENDIX

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기